Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ZRSEF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ZRSEF and 80,000+ other tickers.
See exactly how ZRSEF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ZRSEF and 80,000+ other tickers.
DocMorris AG, an enterprise headquartered in Frauenfeld, Switzerland, and founded in 1993, operates a dual business model encompassing e-commerce pharmacies and a wholesale distribution network for medical and pharmaceutical goods. Its market reach extends both within Switzerland and across international borders. The company's diverse offerings include consumer health, beauty, and personal care items, alongside services focused on medication management. Furthermore, DocMorris AG maintains physical pharmacy locations. It directly supplies its products to various clients, including medical…
DocMorris AG (ZRSEF) Q2 2026 Earnings Call Transcript
DocMorris AG (ZRSEF) Q1 2026 Earnings Call Transcript
DocMorris AG (ZRSEF) Q4 2025 Earnings Call Transcript
DocMorris AG (OTCPK:ZRSEF) Q2 2025 Earnings Conference Call August 19, 2025 5:00 AM ET Company Participants Daniel Wüest - CFO & Member of Executive Board Walter Hess - CEO & Member of Executive Board Conference Call Participants Gian-Marco Werro - Zürcher Kantonalbank, Research Division Sebastian Vogel - UBS Investment Bank, Research Division Urs Kunz - Research Partners AG Volker Bosse - Baader-Helvea Equity Research Walter Hess Good morning, everybody, and thank you for joining today's conference call, which will be hosted by Daniel Wüest, our CFO, and me. Let me start by giving you a quick overview of the key highlights from the first half of 2025.
DocMorris AG (OTCPK:ZRSEF) Q4 2024 Earnings Conference Call March 13, 2025 6:00 AM ET Company Participants Walter Hess - Chief Executive Officer Daniel Wüest - Chief Financial Officer Conference Call Participants Olivier Calvet - UBS Jan Koch - Deutsche Bank Yannik Siering - Stifel Urs Kunz - Research Partners Gian Marco Werro - Zurcher KB Michael Heider - Warburg Research Christopher Johnen - HSBC Operator Hello, ladies and gentlemen and welcome to the DocMorris AG 2024 Full Year Results and Outlook 2025. At this time, all participants have been placed on a listen-only mode.